within Pharmacolibrary.Drugs.ATC.S;

model S01EE02
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.00016666666666666666,
    adminDuration  = 600,
    adminMass      = 28 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0002,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>S01EE02</td></tr><td>route:</td><td>ophthalmic</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Unoprostone is a prostaglandin analog used as an ophthalmic solution for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It is not widely used today, as newer agents are generally preferred; its use is limited in several countries.</p><h4>Pharmacokinetics</h4><p>No published human pharmacokinetic studies reporting compartmental pharmacokinetic parameters for unoprostone. Parameters below are theoretical estimates based on its similarity to other ophthalmic prostaglandin analogs.</p><h4>References</h4><ol><li><p>Ravinet, E, et al., &amp; Brignoli, R (2003). Four years later: a clinical update on latanoprost. <i>European journal of ophthalmology</i> 13(2) 162–175. DOI:<a href=\"https://doi.org/10.1177/112067210301300208\">10.1177/112067210301300208</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12696636/\">https://pubmed.ncbi.nlm.nih.gov/12696636</a></p></li><li><p>Nagai, N, et al., &amp; Abe, T (2016). Long-Term Protection of Genetically Ablated Rabbit Retinal Degeneration by Sustained Transscleral Unoprostone Delivery. <i>Investigative ophthalmology &amp; visual science</i> 57(15) 6527–6538. DOI:<a href=\"https://doi.org/10.1167/iovs.16-20453\">10.1167/iovs.16-20453</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27918826/\">https://pubmed.ncbi.nlm.nih.gov/27918826</a></p></li><li><p>Kashiwagi, K, et al., &amp; Tsukahara, S (1999). Metabolites of isopropyl unoprostone as potential ophthalmic solutions to reduce intraocular pressure in pigmented rabbits. <i>Japanese journal of pharmacology</i> 81(1) 56–62. DOI:<a href=\"https://doi.org/10.1254/jjp.81.56\">10.1254/jjp.81.56</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10580371/\">https://pubmed.ncbi.nlm.nih.gov/10580371</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end S01EE02;
